Stem cells for vascular tissue engineering; signaling pathways in cell-cell adhesion and wound healing; lentiviral vectors and lentiviral microarrays for high-throughput gene expression analysis and gene discovery
908 Furnas Hall
Buffalo NY, 14260
Phone: (716) 645-1202
Stelios T. Andreadis received his MS (Applied Mathematics) and PhD degree in Chemical Engineering from the University of Michigan studying the dynamics of retroviral gene transfer for gene therapy. He then pursued postdoctoral training at the Center for Engineering in Medicine at Harvard Medical School, where he worked in the areas of gene therapy, tissue engineering and regenerative medicine. Currently he serves as SUNY Distinguished Professor of Chemical and Biological Engineering, Biomedical Engineering and Member of the Center of Excellence in Bioinformatics and Life Sciences at the University at Buffalo, State University of New York. He is the Director of the Cell, Gene and Tissue Engineering Center and served as the Director of the Stem Cells in Regenerative Medicine (SCiRM) Training Program that was funded by NYSTEM to train students in stem cell biology and bioengineering and applications of stem cells in regenerative medicine. He served as CBE department Chair for two terms from 2012 to 2018.
His research interests span a wide spectrum from fundamental to technological to pre-clinical/translational research. He has made significant research contributions in the areas of stem cell bioengineering; vascular, skin and gland tissue engineering and regeneration; molecular design of biomaterials; protein and gene delivery, and lentiviral arrays for high throughout pathway analysis of stem cell differentiation and reprogramming. He co-founded a company (Angiograft, LLC) to commercialize the cell-free vascular grafts that were developed in his laboratory as arterial replacement grafts for treatment of cardiovascular disease.
Professor Andreadis’ research has received continuous funding since 1999 from NIH, NSF, NYSTEM and private foundations (Whitaker, Oishei), totaling more than $20 million. He is the recipient the Whitaker Foundation Young Investigator Award (1999), the NSF CAREER Award (2000), the Exceptional Scholar Young Investigator Award (UB, 2003), Exceptional Scholar: Sustained Achievement Award (UB, 2009) and the SUNY Chancellor’s Award for Excellence in Scholarship (2014). He was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE, 2009) and of the Biomedical Engineering Society (BMES, 2016). In 2018 he was promoted to the rank of SUNY Distinguished Professor. He has published 140 peer-reviewed publications and conference proceedings and delivered more than 75 invited seminars. He has advised 28 PhD students, 18 MS students, 4 post-doctoral research fellows and more than 40 undergraduate researchers.
His former PhD students hold tenured or tenure-track academic positions (U of South Florida, UB, IIT Kanpur in India, The Capital University of Medical Sciences in Beijing, China); post-doctoral positions at top Universities (Harvard, Stanford, Johns Hopkins, Univ. of Pennsylvania); or research and leadership positions in leading pharmaceutical/biotechnology companies (Shire Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Life Technologies, MedImmune and others).